IVRO — InVitro International Share Price
Last trade - 00:00- $2.26m
- $1.89m
- $0.72m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.94 | ||
| Price to Tang. Book | 3.94 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.15 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.3% | ||
| Return on Equity | 1.09% | ||
| Operating Margin | -1.84% | ||
Financial Summary
| Year End 30th Sep | Unit | 2006 | 2007 | 2008 | 2009 | 2010 | 2011E | 2012E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.61 | 0.74 | 0.7 | 0.76 | 0.72 | n/a | n/a | 1.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +6.74 | +333.68 | -6.07 | -22.22 | -88.37 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Invitro International is a technology-driven provider of non-animal testing methods. The Company’s testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its technologies are commercialized through test kits and laboratory services globally. It operates in various industry segments providing in-vitro (non-animal) consumer, product and environmental safety test methods to customers in the cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation industries. Its Irritection Assay System is a vitro test method which uses changes of relevant macromolecules to predict the ocular and dermal irritancy of chemicals, mixtures and product formulations. Its Irritection Assay System consists of an ocular test, Ocular Irritection and dermal test, Dermal Irritection. Corrositex is a non-animal test that determines skin corrosivity.
Directors
- Irwin Gruverman CHM (78)
- W. Richard Ulmer CEO (59)
- Dennis Chenoweth DRC (57)
- William Curtis DRC (61)
- David Reed DRC (73)
- Jeffrey Safchik DRC (69)
- Last Annual
- September 30th, 2010
- Last Interim
- September 30th, 2010
- Incorporated
- September 19th, 1985
- Public Since
- May 16th, 1991
- No. of Employees
- 16
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 22,759,809
- Address
- 330 E Orangethorpe Ave Ste D, PLACENTIA, 92870
- Web
- https://www.invitrointl.com/
- Phone
- +1 9498518356
- Auditors
- McGladrey & Pullen, LLP
Upcoming Events for IVRO
Similar to IVRO
Acusphere
Pink Sheets on Nasdaq
Adaptimmune Therapeutics
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 20:22 UTC, shares in InVitro International are trading at $0.10. This share price information is delayed by 15 minutes.
Shares in InVitro International last closed at $0.10 and the price had moved by -11.74% over the past 365 days. In terms of relative price strength the InVitro International share price has underperformed the S&P500 Index by -24.46% over the past year.
There is no consensus recommendation for this security.
Find out moreInVitro International does not currently pay a dividend.
InVitro International does not currently pay a dividend.
InVitro International does not currently pay a dividend.
To buy shares in InVitro International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.10, shares in InVitro International had a market capitalisation of $2.26m.
Here are the trading details for InVitro International:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: IVRO
Based on an overall assessment of its quality, value and momentum InVitro International is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like InVitro International. Over the past six months, its share price has outperformed the S&P500 Index by +36.2%.
As of the last closing price of $0.10, shares in InVitro International were trading +32.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The InVitro International PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
InVitro International's management team is headed by:
- Irwin Gruverman - CHM
- W. Richard Ulmer - CEO
- Dennis Chenoweth - DRC
- William Curtis - DRC
- David Reed - DRC
- Jeffrey Safchik - DRC